|
Post by brotherm1 on May 6, 2020 17:59:50 GMT -5
Mango, who said it is highly likely that after successful TreT clinical trials and/or successful FDA approval of TreT—UTHR will trigger the green light to advance the second molecule, Tadalafil, for PAH?
|
|
|
Post by mango on May 6, 2020 18:06:32 GMT -5
Wow brother, I just said it was highly likely. Logic and common sense tells me so. If I was Martine Rothblatt I would want to see TreT be approved first so I know that MannKind's got what I need to have not only successful clinical trials, but a successful FDA approval, before investing more money, time and resources into the Company. But, I am sure you have an opinion that is opposite.
|
|
|
Post by sportsrancho on May 6, 2020 18:37:55 GMT -5
If you guys can spend some time acquiring more followers on Twitter that would be helpful, just concentrate on following doctors, Endo’s, diabetic associations.. anybody that you want to spread the word to. If you retweet what they say they’ll usually follow you ...you don’t get followers by magic it takes work. 👍🏻
|
|
|
Post by mango on May 6, 2020 18:46:39 GMT -5
Harry's tweets are always really good. Nice work
|
|
|
Post by mango on May 6, 2020 19:03:51 GMT -5
|
|
|
Post by robert on May 6, 2020 19:12:16 GMT -5
Just listened to the conference call. The only ones really prospering are the relatively few customers who have figured out how to use the drug, and the executive team with their mostly 6-7 figure compensation packages. Unfortunately, the CEO and his crew are not change agents whatsoever. As long as they are running the company the status quo will prevail. I'm sure they are relatively content with the status quo and won't be going anywhere. It's very sad and depressing that Al Mann created this brilliant product/technology but was simply too late in his life to see it through to success. I am just so beyond disgusted that these middle management box checkers without a creative bone in their body get to ride his coat tails while early investors have been diluted into oblivion suffer- not to mention the millions of diabetes sufferers that don't even know about the drug or have meaningful access to it. I wouldn't have ever believed that sales aren't even remotely close to $100 million annually so long after approval. FWIW, I think this stock is fairly valued (roughly) given the pathetic (my characterization) Afrezza sales figures and the pathetic growth rate of sales. CAVEAT: Any investor has the added potential "thrill" of waking up on any given morning to find the rug pulled out from under him (e.g. dilution, hit piece coordinated with a short attack, etc.). You can kind of make money trading it (which I've done over the years). But it is essentially an un-investable stock. I'm still long and holding just in case some miracle happens. Just ranting I guess...
|
|
|
Post by tingtongtung on May 6, 2020 20:43:15 GMT -5
After several years of listening, I skipped the earnings conf call. I read that the music was different today (I chose my name based on the music in those calls all these years!)
There was no dilution, repeat of Christmas massacre, etc..
I wonder if MNKD hits the bottom this qtr, and raises from now on? DXCM, TNDM, PODS and this..
The new discussion makes it look like MNKD has to survive in spite of Afrezza, not because of Afrezza. Sad as Afrezza has so much potential, and no one seems to know how to sell it.
I'm out of MNKD except for some 2/3K. Was waiting for dilution to get back in today. May be I will wait a little more time.
|
|
|
Post by bones1026 on May 6, 2020 21:14:44 GMT -5
Just listened to the conference call. The only ones really prospering are the relatively few customers who have figured out how to use the drug, and the executive team with their mostly 6-7 figure compensation packages. Unfortunately, the CEO and his crew are not change agents whatsoever. As long as they are running the company the status quo will prevail. I'm sure they are relatively content with the status quo and won't be going anywhere. It's very sad and depressing that Al Mann created this brilliant product/technology but was simply too late in his life to see it through to success. I am just so beyond disgusted that these middle management box checkers without a creative bone in their body get to ride his coat tails while early investors have been diluted into oblivion suffer- not to mention the millions of diabetes sufferers that don't even know about the drug or have meaningful access to it. I wouldn't have ever believed that sales aren't even remotely close to $100 million annually so long after approval. FWIW, I think this stock is fairly valued (roughly) given the pathetic (my characterization) Afrezza sales figures and the pathetic growth rate of sales. CAVEAT: Any investor has the added potential "thrill" of waking up on any given morning to find the rug pulled out from under him (e.g. dilution, hit piece coordinated with a short attack, etc.). You can kind of make money trading it (which I've done over the years). But it is essentially an un-investable stock. I'm still long and holding just in case some miracle happens. Just ranting I guess... Robert, seems you’ve been through the same pain and agony we all have these past few years. Appreciate you joining pro boards today to let us know we’re not alone.
|
|
|
Post by brotherm1 on May 6, 2020 21:38:45 GMT -5
Wow brother, I just said it was highly likely. Logic and common sense tells me so. If I was Martine Rothblatt I would want to see TreT be approved first so I know that MannKind's got what I need to have not only successful clinical trials, but a successful FDA approval, before investing more money, time and resources into the Company. But, I am sure you have an opinion that is opposite. I was just asking. i thought maybe you heard that from MC or M Rothblat
|
|
|
Post by falconquest on May 6, 2020 21:39:49 GMT -5
Just listened to the conference call. The only ones really prospering are the relatively few customers who have figured out how to use the drug, and the executive team with their mostly 6-7 figure compensation packages. Unfortunately, the CEO and his crew are not change agents whatsoever. As long as they are running the company the status quo will prevail. I'm sure they are relatively content with the status quo and won't be going anywhere. It's very sad and depressing that Al Mann created this brilliant product/technology but was simply too late in his life to see it through to success. I am just so beyond disgusted that these middle management box checkers without a creative bone in their body get to ride his coat tails while early investors have been diluted into oblivion suffer- not to mention the millions of diabetes sufferers that don't even know about the drug or have meaningful access to it. I wouldn't have ever believed that sales aren't even remotely close to $100 million annually so long after approval. FWIW, I think this stock is fairly valued (roughly) given the pathetic (my characterization) Afrezza sales figures and the pathetic growth rate of sales. CAVEAT: Any investor has the added potential "thrill" of waking up on any given morning to find the rug pulled out from under him (e.g. dilution, hit piece coordinated with a short attack, etc.). You can kind of make money trading it (which I've done over the years). But it is essentially an un-investable stock. I'm still long and holding just in case some miracle happens. Just ranting I guess... Robert, seems you’ve been through the same pain and agony we all have these past few years. Appreciate you joining pro boards today to let us know we’re not alone.Are you substantiating the old adage that misery loves company? ;-)
|
|
|
Post by bones1026 on May 6, 2020 23:21:01 GMT -5
Robert, seems you’ve been through the same pain and agony we all have these past few years. Appreciate you joining pro boards today to let us know we’re not alone. Are you substantiating the old adage that misery loves company? ;-) [b No. I was being a bit sarcastic
|
|
|
Post by nylefty on May 6, 2020 23:31:28 GMT -5
|
|
|
Post by wgreystone on May 7, 2020 1:31:37 GMT -5
Did MC mention the following two key matrix: 1) retention rate, 2) growth of new prescribers?
|
|
|
Post by Clement on May 7, 2020 7:42:51 GMT -5
Earnings beat "...earnings surprise of 50%". "MannKind (MNKD) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.06." Revenue beat " revenues of $16.24 million for the quarter ended March 2020, surpassing the Zacks Consensus Estimate by 7.16%" finance.yahoo.com/news/mannkind-mnkd-reports-q1-loss-211509165.html
|
|
|
Post by mytakeonit on May 7, 2020 13:12:56 GMT -5
And as promised ... I added more shares of MNKD. Oh, and I also added more shares of SENS. Makes sense to me ! But, that's mytakeonit
|
|